Back to top
more

MediWound (MDWD)

(Delayed Data from NSDQ)

$17.84 USD

17.84
61,743

+0.04 (0.22%)

Updated May 15, 2024 04:00 PM ET

After-Market: $17.84 0.00 (0.00%) 6:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will MediWound (MDWD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and -15.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) Jumps: Stock Rises 9.4%

by Zacks Equity Research

MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers

by Zacks Equity Research

Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers

Nitish Marwah headshot

4 Profitable Stocks to Boost Returns Using Net Income Ratio

by Nitish Marwah

Investors always look for companies with a high level of profitability regardless of the present market condition.

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 35.71% and 4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -8.33% and 32.86%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 15.38% and 92.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: MediWound (MDWD) Q3 Earnings Expected to Decline

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 20.00% and 194.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -7.14% and -23.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

by Zacks Equity Research

Small drugmakers, in general, are having a decent year, despite failures of key pipeline candidates in pivotal studies.

MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 42.11% and -17.97%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 25.00% and 7.96%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    4 Drug Stocks Poised to Surprise this Earnings Season

    by Zacks Equity Research

    Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.

      Why Earnings Season Could Be Great for MediWound (MDWD)

      by Zacks Equity Research

      MediWound (MDWD) looks like an exciting pick for investors as it is poised to beat at earnings season.

        Earnings Estimates Moving Higher for MediWound (MDWD): Time to Buy?

        by Zacks Equity Research

        MediWound (MDWD) could be a solid choice for investors as it has seen estimates moving sharply higher over the past four weeks.

          Brian Hamilton headshot

          Bear of the Day: Valeant Pharma (VRX)

          by Brian Hamilton

          The company is facing legal, accounting, and negative pricing issues.